Late effects of childhood cancer: Life-threatening issues

Journal of Nippon Medical School

Volumn 75, Issue 6, 2008, Pages 320-324

  Maeda, Miho ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cardiotoxicity; Childhood cancer; Late effects; Second neoplasm; Survivors of childhood cancer

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; DOXORUBICIN; GYRASE INHIBITOR; RAZOXANE; UNCLASSIFIED DRUG; ZIECARD;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CHILDHOOD CANCER; COMPARATIVE STUDY; ECG ABNORMALITY; GENETIC PREDISPOSITION; HEART FAILURE; HODGKIN DISEASE; HUMAN; KIDNEY TUMOR; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; OSTEOSARCOMA; PAPILLARY CARCINOMA; RADIATION DOSE; REVIEW; SECOND CANCER; STEM CELL TRANSPLANTATION; THYROID CANCER;

ANTHRACYCLINES; CHILD; HEART DISEASES; HUMANS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY;

EID: 58149214041     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.75.320     Document Type: Review

References (30)

1. Hampton T: Cancer tratment's trade-off: years of added life can have long-term costs. JAMA 2005; 294: 167-168.
2. Mertens AC, Yasui Y, Neglia JP, et al.: Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001; 19: 3163-3172.
3. Neglia JP, Friedman DL, Yasui Y, et al.: Second malignant neoplasms in five year survivors of childhood cancer. Childhood Cancer Survivors Study. J Natl Cancer Inst 2001; 93: 618-629.
4. Argani P, Lae M, Ballard ET, et al.: Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 2006; 24: 1529-1534.
5. Bassal M, Mertens AC, Taylor L, et al.: Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivors Study. J Clin Oncol 2006; 24: 476-483.
6. Inskip PD: Second cancers following radiotherapy. In multiple primary cancers (Neught AI, Meadows AT, Robison E, eds), 1999; pp 91-136, Lippincott Williams and Wilkins, Philadelphia.
7. Perkins JI, Liu Y, Mitby PA, et al.: Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23: 3733-3741.
8. Sigurdson AJ, Ronckers CM, Mertens AC, et al.: Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005; 365: 2014-2023.
9. Hawkins MM, Wilson LM, Burton BS, et al.: Radiation, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88: 270-278.
10. Pui CH, Ribeiro RG, Hancock ML, et al.: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682-1687.
11. Davies SM: Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol 2001; 36: 536-540.
12. Relling MV, Boyett JM, Blanco JG, et al.: Granulocyte colony-stimulating factor and risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 11: 3862-3867.
13. Neglia JP, Robison LL, Stovall M, et al.: New primary neoplasms of the central nervous system in survivors of childhood vancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006; 98: 1528-1537.
14. Relling MV, Rubnitz JE, Rivera GK, et al.: High incidence of secondary brain tumors after radiotherapy and antimetabolites. Lancet 1999; 354: 34-39.
15. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL: New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-1358.
16. Bhatia S, Ramsay NK, Steinbuch M, et al.: Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
17. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA: Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. L Clin Oncol 2001; 19: 191-196.
18. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-1677.
19. Siber JH, Jakacki RI, Larsen RL, Goldwein JW, Barner G: Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993; 21: 477-479.
20. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815.
21. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE: Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007; 8: 1039-1058.
22. Elliot P: Pathogenesis of cardiotoxicity induced by anthoracyclines. Semin Oncol 2007; 33: S2-S7.
23. Fukazawa R, Ogawa S, Hirayama T: Early detection of anthracycline cardiotoxicity in children with acute leukemia using exercise-based echocardiography and Doppler echocardiography. Jpn Circulation J 1994; 58: 625-634.
24. Hamada H, Ohkubo T, Maeda M, Ogawa S: Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatr International 2006; 48: 313-320.
25. Fukumi D, Uchikoba Y, Maeda M, Ogawa S: Longitudinal evaluation of cardiotoxicity by signal-averaged electrocardiography in children with cancer. Peiatr International 2002; 44: 134-140.
26. Lipshultz SE, Giantris AL, Lipsitz SR, et al.: Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 2002; 20: 1677-1682.
27. Lipshultz SE, Rifai N, Dalton VM, et al.: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-153.
28. Tebbi CK, London WB, Friedman D, et al.: Dexrazoxane-associatedrisk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25: 493-500.
29. Barry EV, Vrooman LM, Dahlberg SE, et al.: Absent of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with Dexrazone. L Clin Oncol 2008; 26: 1106-1110.
30. Oeffinger KC, Mertens AC, Skler CA, et al.: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-1882.